On Mar. 9, 2018, Boston-based cancer company Partner Therapeutics announced that it had acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi. Leukine is an immuno-stimulant that promotes the growth and activation of a broad range of white blood cells important in activating the body’s immune response to fight infections.

PTx also acquired a dedicated manufacturing facility in Lynnwood, a state of the art biologics manufacturing plant that was certified for commercial production in 2012. The Lynnwood facility serves as the core manufacturing and supply chain center for PTx’s operations.